Sofosbuvir 400 mg Velpatasvir 100 mg Tablets

Description

Sofosbuvir 400 mg Velpatasvir 100 mg Tablets is the global oral tablet for pan-genotypic Chronic Hepatitis C treatment. This combination (Sofosbuvir 400 mg + Valpatasvir 100 mg) drug has been approved by US FDA European Commission for treatment of patients with all genotypic Chronic Hepatitis C virus infection. VELPANAT is used without cirrhosis or with compensated cirrhosis, and patients with advanced cirrhosis (Decompensated). In those with advanced cirrhosis (decompensated), VELPANAT is used with ribavirin. Therapeutic indications Velpanat is indicated for the treatment of adult patients with chronic Hepatitis C Virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infections With or without cirrhosis or with compensated cirrhosis With decompensated cirrhosis for use in combination with Ribavirin